Summary
Dr Reddy's shares dropped 7% after the company delayed commercial supplies of its semaglutide product due to a quality issue with the active pharmaceutical ingredient (API). An investigation is underway to identify the root cause, though patient safety and regulatory filings are reportedly unaffected.